Skip to main content
. 2014 Oct 14;20(38):13767–13774. doi: 10.3748/wjg.v20.i38.13767

Table 4.

Biomarker development process

Phase No. Aim Detail
Phase 1 Preclinical Exploratory Promising directions identified
Phase 2 Clinical Assay and Validation Clinical assay detects established disease
Phase 3 Retrospective Longitudinal Biomarker detects disease early before it becomes clinical and a “screen positive” rule is defined
Phase 4 Prospective Screening Extent and characteristics of disease detected by the test and the false referral rate are identified
Phase 5 Cancer Control Impact of screening on reducing the burden of disease on the population is quantified

Adapted from reference [32].